Basilea Pharmaceutica Yönetim

Yönetim kriter kontrolleri 3/4

Basilea Pharmaceutica CEO'su David Veitch, Apr2018 tarihinde atandı, in görev süresi 6.58 yıldır. in toplam yıllık tazminatı CHF 1.75M olup, şirket hissesi ve opsiyonları dahil olmak üzere 35% maaş ve 65% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.011% ine doğrudan sahiptir ve bu hisseler CHF 56.77K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.8 yıl ve 9.6 yıldır.

Anahtar bilgiler

David Veitch

İcra Kurulu Başkanı

CHF 1.7m

Toplam tazminat

CEO maaş yüzdesi	35.0%
CEO görev süresi	6.6yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	6.8yrs
Yönetim Kurulu ortalama görev süresi	9.6yrs

Son yönetim güncellemeleri

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18

CEO Tazminat Analizi

David Veitch'un ücretlendirmesi Basilea Pharmaceutica'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CHF 652k
Mar 31 2024	n/a	n/a	CHF 5m
Dec 31 2023	CHF 2m	CHF 611k	CHF 10m
Sep 30 2023	n/a	n/a	CHF 33m
Jun 30 2023	n/a	n/a	CHF 56m
Mar 31 2023	n/a	n/a	CHF 34m
Dec 31 2022	CHF 2m	CHF 599k	CHF 12m
Sep 30 2022	n/a	n/a	CHF 6m
Jun 30 2022	n/a	n/a	CHF 851k
Mar 31 2022	n/a	n/a	-CHF 3m
Dec 31 2021	CHF 2m	CHF 594k	-CHF 7m
Sep 30 2021	n/a	n/a	-CHF 26m
Jun 30 2021	n/a	n/a	-CHF 45m
Mar 31 2021	n/a	n/a	-CHF 30m
Dec 31 2020	CHF 1m	CHF 589k	-CHF 15m
Sep 30 2020	n/a	n/a	-CHF 6m
Jun 30 2020	n/a	n/a	CHF 3m
Mar 31 2020	n/a	n/a	-CHF 10m
Dec 31 2019	CHF 1m	CHF 583k	-CHF 22m
Sep 30 2019	n/a	n/a	-CHF 23m
Jun 30 2019	n/a	n/a	-CHF 24m
Mar 31 2019	n/a	n/a	-CHF 28m
Dec 31 2018	CHF 2m	CHF 529k	-CHF 31m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 2.02M ), Swiss pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.47M ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

David Veitch (59 yo)

6.6yrs

Görev süresi

CHF 1,745,679

Tazminat

Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch joined Basilea in...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Veitch	Chief Executive Officer	6.6yrs	CHF 1.75m	0.011% CHF 56.8k
Adesh Kaul	Chief Financial Officer	5.6yrs	Veri yok	0.0041% CHF 21.9k
Gerrit Hauck	Chief Technology Officer	6.5yrs	Veri yok	Veri yok
Laurenz Kellenberger	Chief Scientific Officer	15.8yrs	Veri yok	0.0041% CHF 21.9k
Marc Engelhardt	Chief Medical Officer	6.8yrs	Veri yok	Veri yok
Peer Schroder	Head of Corporate Communications & Investor Relations	no data	Veri yok	Veri yok
Damian Heller	General Counsel & Corporate Secretary	7.3yrs	Veri yok	Veri yok
Andreas Kumin	Head of Corporate Development	no data	Veri yok	Veri yok
Ursula Eberhardt	Head of Global Human Resources	7.8yrs	Veri yok	Veri yok
Mark Jones	Head of Global Affairs	6.8yrs	Veri yok	Veri yok
Peter Bielmeier	Head of Global Quality Management	2.2yrs	Veri yok	Veri yok
Mohammed Benghezal	Head of Biology	no data	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: BSLN 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nicole Onetto	Independent Non-Executive Director	7.6yrs	CHF 192.13k	0.0061% CHF 32.2k
Leonard Kruimer	Independent Non-Executive Director	2.6yrs	CHF 186.88k	Veri yok
Domenico Scala	Independent Chairman of the Board	13yrs	CHF 337.68k	0.0049% CHF 25.8k
Alf Gunnar Nicklasson	Independent Non-Executive Director	11.6yrs	CHF 211.75k	0.015% CHF 76.7k
Carole Sable	Independent Non-Executive Director	1.6yrs	CHF 192.13k	Veri yok
Thomas Werner	Independent Vice-Chairman	13yrs	CHF 224.80k	0.0098% CHF 52.0k

9.6yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BSLN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.6 yıldır).

Basilea Pharmaceutica Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Basilea Pharmaceutica AG, Annual General Meeting, Apr 24, 2024

Basilea Pharmaceutica AG, Annual General Meeting, Apr 26, 2023

High number of new directors

Insufficient new directors

Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Board and as Chairman of the Audit Committee

Recent updates

Basilea Pharmaceutica AG Updates Financial Guidance for the Year 2024

European Commission Approves the Pediatric Use of Basilea Pharmaceutica AG's Antifungal Cresemba® (Isavuconazole)

First half 2024 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Consensus EPS estimates increase by 15%

Price target increased by 7.6% to CHF70.58

Basilea Pharmaceutica AG to Report First Half, 2024 Results on Aug 13, 2024

New minor risk - Negative shareholders equity

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 78%

Price target decreased by 7.6% to CHF69.90

Consensus EPS estimates fall by 30%

Basilea Pharmaceutica AG to Report Fiscal Year 2023 Results on Feb 13, 2024

Basilea Pharmaceutica AG, Annual General Meeting, Apr 24, 2024

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Basilea Pharmaceutica AG Revises Earnings Guidance for the Year 2023

First half 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Price target decreased by 9.0% to CHF67.18

Consensus EPS estimates increase by 13%

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Basilea Pharmaceutica AG to Report First Half, 2023 Results on Aug 15, 2023

Basilea Pharmaceutica Ltd Revises Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG, Annual General Meeting, Apr 26, 2023

Basilea Pharmaceutica AG to Report Fiscal Year 2022 Results on Feb 14, 2023

Price target decreased to CHF68.58

Price target decreased to CHF68.58

Basilea Pharmaceutica AG 's ERADICATE Phase 3 Study Results Highlight the Potential Role of Ceftobiprole in the Treatment of Staphylococcus Aureus Bacteremia (Sab)

Consensus estimates of losses per share improve by 13%

Consensus estimates of losses per share improve by 10%

Basilea Pharmaceutica AG Revises Earnings Guidance for the Full Year 2022

Price target increased to CHF73.98

First half 2022 earnings: EPS and revenues exceed analyst expectations

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Consensus forecasts updated

Basilea Pharmaceutica Ltd. Positive Results of Phase 3 Eradicate Study with Ceftobiprole in Staphylococcus Aureus Bacteremia

Basilea Pharmaceutica AG Reports Progress on the Implementation of Its Strategy to Focus on Anti-Infectives

Basilea Pharmaceutica AG to Report First Half, 2022 Results on Aug 16, 2022

High number of new directors

Price target decreased to CHF77.00

Insufficient new directors

Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Board and as Chairman of the Audit Committee

Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891

Price target decreased to CHF77.50

Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candidate BAL0891 at ESMO TAT congress

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Basilea Pharmaceutica AG Provides Earnings Guidance for the Fiscal Year 2022

Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Amplifications from Phase 2 Study FIDES-01 at ASCO GI Cancers Symposium

Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigating Ceftobiprole in Bloodstream Infections

Forecast to breakeven in 2024

Basilea Pharmaceutica Ltd. Announces FDA Approval of Investigational New Drug Application for Novel Oncology Drug Candidate BAL0891

Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib in Patients with FGFR2 Fusion-Positive iCCA at ESMO Congress

First half 2021 earnings released: CHF1.72 loss per share (vs CHF0.92 profit in 1H 2020)

No longer forecast to breakeven

Basilea Pharmaceutica Ltd. Provides Updates on Efficacy Data with Derazantinib in Bile Duct Cancer and on Ongoing Clinical Programs in Urothelial and Gastric Cancer

Basilea Pharmaceutica AG Wins Carb-X Grant of Up to USD 2.7 Million to Develop Novel-Class Antibiotic

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Basilea Pharmaceutica AG has completed a Follow-on Equity Offering in the amount of CHF 45.75 million.

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

PHT International Inc. entered into an agreement to acquire Basilea Pharmaceutica China Ltd. from Basilea Pharmaceutica AG (SWX:BSLN) for $6.3 million.

Basilea Pharmaceutica Ltd. Reports derazantinib/PD-L1 Checkpoint Inhibitor Combination Results from Dose-Finding Part of FIDES-02 Study in Patients with Solid Tumors at ASCO GU Symposium

Basilea Pharmaceutica Ltd. Promotes Potential First-In-Class Small-Molecule Kinase Inhibitor